Does higher mean platelet volume indicate increased atherothrombotic cardiovascular risk?

The assessment of Mean Platelet Volume (MPV) provides significant insights into platelet physiology and its correlation with cardiovascular risk. Evidence supports the role of MPV as a biomarker for platelet reactivity, with higher values indicating a more prothrombotic state.

Clinical and effectiveness evidence

Research consistently identifies MPV as an independent predictor of adverse cardiovascular outcomes.

• Major Adverse Cardiac Events (MACE): A 2024 meta-analysis of prospective studies involving patients with coronary heart disease demonstrated that high MPV is significantly associated with long-term MACE (Hazard Ratio [HR] 1.14) and a twofold increase in short-term all-cause mortality (HR 2.10).
• Metabolic Populations: In patients with type 2 diabetes, extreme high MPV values—often analyzed in conjunction with total platelet count—correlate with increased rates of myocardial infarction and stroke.
• Demographic Considerations: While the association is well-established in general cardiac populations, specific data for older postmenopausal women remain less robust, though the biological mechanisms are expected to be consistent across demographics.

Mechanistic explanations

The relationship between MPV and cardiovascular risk is driven by the enhanced functional capacity of larger platelets.

• Granule Density: Larger platelets (high MPV) are typically younger and contain a higher concentration of alpha-granules and dense granules. These granules house prothrombotic mediators such as ADP and P-selectin (CD62P), which are released upon activation to drive thrombus propagation.
• Receptor Expression: High-MPV platelets exhibit increased surface expression of glycoprotein (GP) IIb-IIIa and GP Ib receptors. This higher receptor density allows for more robust adhesion and aggregation in response to agonists like thrombin and ADP.
• Metabolic Activity: These platelets are metabolically and enzymatically more active, producing higher levels of thromboxane A2, a potent vasoconstrictor and platelet activator, thereby facilitating a state of heightened thrombotic potential.

Bottom line

Higher MPV serves as a reliable indicator of increased platelet reactivity and is associated with a greater risk of myocardial infarction, stroke, and mortality. Clinically, an elevated MPV suggests a more aggressive prothrombotic phenotype due to the increased granule content and receptor density of larger platelets.